Key result
Implantable cardioverter-defibrillators and pharmacologic therapies form the basis of evidence-based primary prevention of sudden cardiac death in patients with high-risk cardiomyopathies.
This review outlines a rational approach to using pharmacologic and ICD therapies for the primary prevention of sudden cardiac death in patients with high-risk cardiomyopathies.
We present an evidence-based overview of primary prevention of sudden cardiac death. Several recent studies have provided important data regarding pharmacologic and device-based therapy for patients with conditions that confer high risk for sudden death. A rational approach to these therapies, with emphasis on implanted cardiovertor defibrillators, is discussed.
No takes yet. Share an insight, caveat, or question.
Klein et al. (2005) studied this question. Implantable cardioverter-defibrillators and pharmacologic therapies form the basis of evidence-based primary prevention of sudden cardiac death in patients with high-risk cardiomyopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: